

27 May 2019


Dear Healthcare Professional

Additional Supply of FluQuadri under Section 14 of the *Therapeutic Goods Act 1989*

There has been an unprecedented demand for seasonal influenza vaccines this year and this has resulted in a limited availability of influenza vaccines including FluQuadri (manufactured by sanofi pasteur). To address the increase in demand, Sanofi has imported additional doses of FluQuadri for individuals aged 3 years and over. Given that the imported batch (UJ173AA) is packaged using the Standard International labelling, it does not comply with the Australian labelling requirements. It is important to note that the product is the same, the differences that we are noting here are in the labelling and we are writing to you to ensure that you are aware of these differences.

The Standard International labelling is intended for the global market and hence is different to the labelling used in Australia, as highlighted below:

Australian labelling FluQuadri 0.5 mL 3 years & over English	Standard International labelling FluQuadri 0.5 mL 3 years & over English and Spanish
<p>Front panel carton</p> 	<p>Front panel carton</p> 



The package leaflet available in each carton is written in English and Spanish. It states that FluQuadri is approved for use in persons 6 months of age and available in both 0.25 mL and 0.5 mL presentations (as is the case in some international markets). You should note that in Australia, 0.25 mL presentation is available as FluQuadri Junior for use in children aged 6 to 35 months. Consequently the FluQuadri batch UJ173AA should not be used in this population.

Should you have any questions relating to this product, please call Sanofi Pasteur Medical Information at 1800 818 806.

Thank you for your understanding.

Regards,

Dr. Christian T. Felter, MD
Head of Medical, Sanofi Pasteur Australia and New Zealand